Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Research Interest in Bevacizumab Remains Robust

October 6th 2011

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

Dr. McDonald on the Continued Understanding of Bevacizumab

October 6th 2011

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab

A Look Into the Future of Breast Cancer: A Conversation With Joyce A. O'Shaughnessy, MD

October 6th 2011

Leading breast cancer researcher Joyce A. O'Shaughnessy, MD, developed and chaired the 10th International Congress on the Future of Breast Cancer, a 4-day interactive program.

Dr. Rugo on Proliferation as an Anti-Angiogenesis Marker

October 5th 2011

Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker

When Less Is More: An Interview With J. Michael Dixon, MBChB, MD

October 5th 2011

Professor of Surgery and Consultant Surgeon at the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland.

Dr. Morrow on the Z11 Trial Results Changing Practice

October 4th 2011

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center on the Z11 Trial Results Changing Practice

Dr. O'Shaughnessy Describes the School of Breast Oncology

October 3rd 2011

Dr. Joyce A. O'Shaughnessy from the Baylor Sammons Cancer Center Describes the School of Breast Oncology

Dr. Morrow Describes the ACOSOG Z11 Trial

September 30th 2011

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Describes the ACOSOG Z11 Trial

Triptorelin May Thwart Chemotherapy-Induced Early Menopause

September 29th 2011

Temporary ovarian suppression using triptorelin may decrease the rate of early menopause in premenopausal women with early-stage breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

Dr. Mills on the Shifts Towards Personalized Medicine

September 29th 2011

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine

Dr. Dixon on Systems Biology for Combination Therapy

September 28th 2011

Dr. Michael Dixon from University of Edinburgh on Systems Biology Determining Therapy Combinations

Dr. Ellis on Genome Forward Breast Cancer Treatment

September 26th 2011

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

Synchronous Radiotherapy With Chemotherapy Improves Local Control in Early Breast Cancer Patients

September 26th 2011

Radiotherapy can be given between or during chemotherapy cycles, rather than sequentially, for women with early breast cancer.

Vitamin D Eases Musculoskeletal Symptoms in Breast Cancer Patients

September 26th 2011

Weekly high-dose vitamin D supplementation improves joint and muscle pain related to anastrozole therapy in breast cancer patients with low vitamin D levels.

T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast Cancer

September 25th 2011

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

Dr. McDonald on Approved Angiogenesis Inhibitors

September 22nd 2011

Dr. Donald McDonald from UCSF Comprehensive Cancer Center Explains Approved Angiogenesis Inhibitors

Cancer Screening: Are You Recommending the Right Intervals?

September 22nd 2011

Now more than ever, oncology nurses need to be able to fill the knowledge gap and accurately educate their patients and the public about cancer screening tests and their frequency.

Dr. Tripathy Discusses Breast Carcinoma Heterogeneity

September 20th 2011

Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity

Dr. Rugo on VEGF-A as an Avastin Response Predictor

September 16th 2011

Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor

Dr. Dixon on Letrozole With Pathway Inhibitors

September 15th 2011

Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors